Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.
Carreño JM, McDonald JU, Hurst T, Rigsby P, Atkinson E, Charles L, Nachbagauer R, Behzadi MA, Strohmeier S, Coughlan L, Aydillo T, Brandenburg B, García-Sastre A, Kaszas K, Levine MZ, Manenti A, McDermott AB, Montomoli E, Muchene L, Narpala SR, Perera RAPM, Salisch NC, Valkenburg SA, Zhou F, Engelhardt OG, Krammer F. Carreño JM, et al. Vaccines (Basel). 2020 Nov 9;8(4):666. doi: 10.3390/vaccines8040666. Vaccines (Basel). 2020. PMID: 33182279 Free PMC article.
Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology.
Javaid W, Ehni J, Gonzalez-Reiche AS, Carreño JM, Hirsch E, Tan J, Khan Z, Kriti D, Ly T, Kranitzky B, Barnett B, Cera F, Prespa L, Moss M, Albrecht RA, Mustafa A, Herbison I, Hernandez MM, Pak TR, Alshammary HA, Sebra R, Smith ML, Krammer F, Gitman MR, Sordillo EM, Simon V, van Bakel H. Javaid W, et al. Among authors: carreno jm. Clin Infect Dis. 2021 Dec 6;73(11):e4375-e4383. doi: 10.1093/cid/ciaa1781. Clin Infect Dis. 2021. PMID: 33252647 Free PMC article.
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F. Nachbagauer R, et al. Among authors: carreno jm. Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7. Nat Med. 2021. PMID: 33288923 Clinical Trial.
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, Eaker LQ, Ferreri ED, Floda DL, Gleason CR, Hamburger JZ, Jiang K, Kleiner G, Jurczyszak D, Matthews JC, Mendez WA, Nabeel I, Mulder LCF, Raskin AJ, Russo KT, Salimbangon AT, Saksena M, Shin AS, Singh G, Sominsky LA, Stadlbauer D, Wajnberg A, Simon V. Krammer F, et al. Among authors: carreno jm. N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10. N Engl J Med. 2021. PMID: 33691060 Free PMC article. No abstract available.
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD.
Amanat F, Thapa M, Lei T, Sayed Ahmed SM, Adelsberg DC, Carreno JM, Strohmeier S, Schmitz AJ, Zafar S, Zhou JQ, Rijnink W, Alshammary H, Borcherding N, Reiche AG, Srivastava K, Sordillo EM, van Bakel H; Personalized Virology Initiative; Turner JS, Bajic G, Simon V, Ellebedy AH, Krammer F. Amanat F, et al. Among authors: carreno jm. medRxiv [Preprint]. 2021 May 1:2021.03.07.21253098. doi: 10.1101/2021.03.07.21253098. medRxiv. 2021. PMID: 33758878 Free PMC article. Preprint.
85 results